Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Actin dynamics is rapidly regulated by the PTEN and PIP2 signaling pathways leading to myocyte hypertrophy.

Li J, Tanhehco EJ, Russell B.

Am J Physiol Heart Circ Physiol. 2014 Dec 1;307(11):H1618-25. doi: 10.1152/ajpheart.00393.2014. Epub 2014 Sep 26.

2.

Long-term pharmacological activation of PPARgamma does not prevent left ventricular remodeling in dogs with advanced heart failure.

Suzuki G, Khanal S, Rastogi S, Morita H, Mishima T, Anagnostopoulos PV, Nass O, Sharov VG, Tanhehco EJ, Goldstein S, Sabbah HN.

Cardiovasc Drugs Ther. 2007 Feb;21(1):29-36. Epub 2007 Feb 9.

PMID:
17294127
3.

Long-term therapy with the acorn cardiac support device normalizes gene expression of growth factors and gelatinases in dogs with heart failure.

Rastogi S, Gupta RC, Mishra S, Morita H, Tanhehco EJ, Sabbah HN.

J Heart Lung Transplant. 2005 Oct;24(10):1619-25.

PMID:
16210139
4.

Long-term effects of non-excitatory cardiac contractility modulation electric signals on the progression of heart failure in dogs.

Morita H, Suzuki G, Haddad W, Mika Y, Tanhehco EJ, Goldstein S, Ben-Haim S, Sabbah HN.

Eur J Heart Fail. 2004 Mar 1;6(2):145-50.

5.

Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment.

Sabbah HN, Sharov VG, Gupta RC, Mishra S, Rastogi S, Undrovinas AI, Chaudhry PA, Todor A, Mishima T, Tanhehco EJ, Suzuki G.

Circ Res. 2003 Nov 28;93(11):1095-101. Epub 2003 Oct 16.

PMID:
14563716
6.

Effects of long-term monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.

Morita H, Suzuki G, Mishima T, Chaudhry PA, Anagnostopoulos PV, Tanhehco EJ, Sharov VG, Goldstein S, Sabbah HN.

Cardiovasc Drugs Ther. 2002 Sep;16(5):443-9.

PMID:
12652114
7.
8.

Cardiac contractility modulation with nonexcitatory electric signals improves left ventricular function in dogs with chronic heart failure.

Morita H, Suzuki G, Haddad W, Mika Y, Tanhehco EJ, Sharov VG, Goldstein S, Ben-Haim S, Sabbah HN.

J Card Fail. 2003 Feb;9(1):69-75.

PMID:
12612875
9.

Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.

Suzuki G, Mishima T, Tanhehco EJ, Sharov VG, Todor A, Rostogi S, Gupta RC, Chaudhry PA, Anagnostopoulos PV, Nass O, Goldstein S, Sabbah HN.

Br J Pharmacol. 2003 Jan;138(2):301-9.

10.

Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.

Suzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanhehco EJ, Rudolph AE, McMahon EG, Goldstein S, Sabbah HN.

Circulation. 2002 Dec 3;106(23):2967-72.

PMID:
12460880
11.

Effects of chronic neutral endopeptidase inhibition on the progression of left ventricular dysfunction and remodeling in dogs with moderate heart failure.

Mishima T, Tanimura M, Suzuki G, Todor A, Sharov VG, Tanhehco EJ, Goldstein S, Sabbah HN.

Cardiovasc Drugs Ther. 2002 May;16(3):209-14.

PMID:
12374898
12.

Hypoxia-induced cleavage of caspase-3 and DFF45/ICAD in human failed cardiomyocytes.

Todor A, Sharov VG, Tanhehco EJ, Silverman N, Bernabei A, Sabbah HN.

Am J Physiol Heart Circ Physiol. 2002 Sep;283(3):H990-5.

13.

Therapeutic potential of complement inhibitors in myocardial ischaemia.

Lucchesi BR, Tanhehco EJ.

Expert Opin Investig Drugs. 2000 May;9(5):975-91. Review.

PMID:
11060721
14.
15.

Preconditioning reduces myocardial complement gene expression in vivo.

Tanhehco EJ, Yasojima K, McGeer PL, McGeer EG, Lucchesi BR.

Am J Physiol Heart Circ Physiol. 2000 Sep;279(3):H1157-65.

16.

Free radicals upregulate complement expression in rabbit isolated heart.

Tanhehco EJ, Yasojima K, McGeer PL, Washington RA, Lucchesi BR.

Am J Physiol Heart Circ Physiol. 2000 Jul;279(1):H195-201.

17.

Acute cocaine exposure up-regulates complement expression in rabbit heart.

Tanhehco EJ, Yasojima K, McGeer PL, Lucchesi BR.

J Pharmacol Exp Ther. 2000 Jan;292(1):201-8.

PMID:
10604949
18.

Preconditioning reduces tissue complement gene expression in the rabbit isolated heart.

Tanhehco EJ, Yasojima K, McGeer PL, Washington RA, Kilgore KS, Homeister JW, Lucchesi BR.

Am J Physiol. 1999 Dec;277(6):H2373-80. doi: 10.1152/ajpheart.1999.277.6.H2373.

PMID:
10600858
19.

The anti-factor D antibody, MAb 166-32, inhibits the alternative pathway of the human complement system.

Tanhehco EJ, Kilgore KS, Liff DA, Murphy KL, Fung MS, Sun WN, Sun C, Lucchesi BR.

Transplant Proc. 1999 Aug;31(5):2168-71. No abstract available.

PMID:
10456004
20.

Ex vivo reversal of heparin-mediated cardioprotection by heparinase after ischemia and reperfusion.

Kilgore KS, Tanhehco EJ, Naylor KB, Lucchesi BR.

J Pharmacol Exp Ther. 1999 Sep;290(3):1041-7.

PMID:
10454476
21.

Reduction of myocardial infarct size after ischemia and reperfusion by the glycosaminoglycan pentosan polysulfate.

Tanhehco EJ, Kilgore KS, Naylor KB, Park JL, Booth EA, Lucchesi BR.

J Cardiovasc Pharmacol. 1999 Jul;34(1):153-61.

PMID:
10413082
22.

The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart.

Kilgore KS, Naylor KB, Tanhehco EJ, Park JL, Booth EA, Washington RA, Lucchesi BR.

J Pharmacol Exp Ther. 1998 Jun;285(3):987-94.

PMID:
9618399
23.

Attenuation of interleukin-8 expression in C6-deficient rabbits after myocardial ischemia/reperfusion.

Kilgore KS, Park JL, Tanhehco EJ, Booth EA, Marks RM, Lucchesi BR.

J Mol Cell Cardiol. 1998 Jan;30(1):75-85.

PMID:
9500866
24.

Reduction of myocardial infarct size in vivo by carbohydrate-based glycomimetics.

Kilgore KS, Tanhehco EJ, Park JL, Naylor KB, Anderson MB, Lucchesi BR.

J Pharmacol Exp Ther. 1998 Jan;284(1):427-35.

PMID:
9435207
25.

Reviparin-sodium prevents complement-mediated myocardial injury in the isolated rabbit heart.

Park JL, Tanhehco EJ, Kilgore KS, Gralinski MR, Lucchesi BR.

J Cardiovasc Pharmacol. 1997 Nov;30(5):658-66.

PMID:
9388049
26.

Protective Effects of Ranolazine on Ventricular Fibrillation Induced by Activation of the ATP-Dependent Potassium Channel in the Rabbit Heart.

Gralinski MR, Chi L, Park JL, Friedrichs GS, Tanhehco EJ, McCormack JG, Lucchesi BR.

J Cardiovasc Pharmacol Ther. 1996 Apr;1(2):141-148.

PMID:
10684411
27.

Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart.

Chi L, Park JL, Friedrichs GS, Banglawala YA, Perez MA, Tanhehco EJ, Lucchesi BR.

Br J Pharmacol. 1996 Mar;117(6):1261-9.

Supplemental Content

Loading ...
Support Center